Stephen G. Swisher

The University of Texas MD Anderson Cancer Center

Papers

7

Total Citations

283

H-Index

7

About

Stephen G. Swisher is a leading thoracic surgeon whose research is reshaping the surgical management of non–small cell lung cancer (NSCLC). His work centers on two transformative areas: integrating immunotherapy into the perioperative setting and advancing minimally invasive surgical techniques. Swisher’s major contributions include leading the landmark NEOSTAR trial, which demonstrated that neoadjuvant nivolumab, alone or with ipilimumab, yields high pathological response rates and manageable surgical outcomes in NSCLC patients—a paradigm shift documented in his 2022 paper (94 citations). He is also a pioneer in robotic-assisted thoracic surgery, with a comprehensive 2019 study (92 citations) showing that robotic lobectomy offers excellent outcomes and low morbidity. Beyond technique, Swisher has driven opioid stewardship in thoracic surgery, publishing an enhanced recovery program that achieved sustained reductions in discharge opioid prescriptions (2021, 9 citations). His work has been cited over 275 times across these key papers, reflecting its profound impact on clinical practice. A prolific investigator and surgeon, Swisher continues to define the future of lung cancer surgery through rigorous clinical trials and innovative perioperative care.

Research Focus

Key Achievements

7
H-Index
7
Papers
283
Total Citations
40
Avg Citations/Paper
🏆 Most Cited Paper
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer
94 citations · 2022
📈 Most Prolific Year: 2019 (2 Papers)
🤝 Key Collaborators: 52
🏛 Institutions: The University of Texas MD Anderson Cancer Center

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago